



Press release |

IBA opens a European R&D and radiopharmaceutical production centre in Fleurus

Embargo until 5.40 pm (Belgian time) – 20th April 2007

Louvain-la-Neuve, Belgium, 20th April 2007 - IBA (Ion Beam Applications S.A.: Reuters IOBAAt.BR and Bloomberg IBAB.BB) has today announced the inauguration of its production site for radiopharmaceutical products in Fleurus, Belgium. The IBA site is on the site of the IRE (Institut National des Radioéléments – National Radioelements Institute).

An inauguration ceremony took place in Fleurus this afternoon in the presence of Mr Elio Di Rupo, the Minister-President of the Walloon Government, the management of the IRE (Institut National des Radioéléments) and the management of IBA.

This new production site has a 14 MeV (Million Electron Volts) new technology cyclotron. This is the only cyclotron of its kind in the world: it can be used both for very high-level industrial production operations – with a capacity which is 10 times greater than that of existing cyclotrons – and for numerous scientific research projects. IBA will be able to supply sufficient quantities of radiopharmaceutical products from its Fleurus site in order to cope with large-scale clinical trials throughout Europe.

Today's inauguration gets the setting up of the Fleurus site underway. There will be three phases:

- The development of a European R&D centre which will allow the company to develop and produce new generation radiopharmaceutical tracers for clinical tests, such as fluorinated tracers – fluorine-18 fluorothymidine (F-18 FLT), fluoromisonidazole (F-Miso), 18F-choline – and other tracers such as iodine 124 (I-124) and copper 64 (Cu64).
- In 2008, IBA will be starting the production and distribution of PET (positron emission tomography) radiopharmaceuticals, mainly FDG (fluorodeoxyglucose), from its Fleurus site in Belgium. Due to the fact that the new cyclotron's production capacity is quite unique worldwide, the distribution will be able both to reach the whole of Europe and to act as support to the other IBA production centres. This will help the company to respond to the growing demand for these radiopharmaceutical agents which are used in molecular imaging
- The site will also act as a centre of excellence and training centre in the field of research into and the production of positron tracers meeting the very highest quality standards.

IBA has invested a total of more than €6 million in the Fleurus site, and the financing for it includes recoupable advances from the Walloon Region. 30 people will be employed there by the end of 2009.

“Once again IBA is proving that it is a major player in the field of radiopharmaceutical products. The setting up of Fleurus reflects IBA's commitment to developing PET scanning in Europe. So IBA is



Press release |

providing itself with the resources to extend the procurement of FDG and make it more reliable, but also to now start supplying European research programmes with tomorrow's molecules", said Pierre Mottet, Chief Executive Officer of IBA. "The Fleurus site is the result of the IBA group's two main assets: expertise in the development of cyclotrons combined with the strength of a worldwide distribution network for radiopharmaceutical products", Mr Mottet added.

ABOUT IBA

IBA develops very high precision solutions used to diagnose and treat cancer. The company also offers sterilisation and ionisation solutions to optimise health and safety on a daily basis. IBA is quoted on the pan-European EURONEXT stock exchange and is part of both the NextEconomy market segment and the BelMid index.

Website: www.iba-worldwide.com.

IBA is organised into two sectors of business:

- The Production and Distribution of Radioisotopes which covers the production and distribution of radiopharmaceutical tracers used in medical imaging, the main one being FDG (F-18 Fluorodeoxyglucose);
- The Technology & Equipment sector which forms the technological basis for a number of the company's activities and covers the development, manufacturing, marketing and services linked to the equipment, including particle accelerators, for imaging, therapy, dosimetry or sterilisation and ionisation.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations

Tel.: +32 10 47 58 16

paul-emmanuel.goethals@iba-group.com

